Plerixafor for pathogen‐agnostic treatment in murine thigh infection and zebrafish sepsis

• Main Authors: Martin O. Evans (Author), Darren M. Smith (Author), Adrian T. Kress (Author), Robert J. Nadeau (Author), Daniel J. Selig (Author), Diana Caridha (Author), Ratanachat Racharaks (Author), Thomas Langowski (Author), Michael S. Madejczyk (Author), Chance Carbaugh (Author), David Saunders (Author), Mark Widder (Author), Jason De Meese (Author), Patricia J. Lee (Author), Jesse P. DeLuca (Author)
• Format: Book
• Published: Wiley, 2024-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Plerixafor is a CXCR4 antagonist approved in 2008 by the FDA for hematopoietic stem cell collection. Subsequently, plerixafor has shown promise as a potential pathogen‐agnostic immunomodulator in a variety of preclinical animal models. Additionally, investigator‐led studies demonstrated ple...